References
- Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular
immunologic mechanisms in patients with atopic dermatitis. J Allergy
Clin Immunol. 2016;138(2):336‐349
- Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine in
patients with allergic diseases: Airway diseases and atopic
dermatitis-PRACTALL document of the European Academy of Allergy and
Clinical Immunology and the American Academy of Allergy, Asthma &
Immunology. J Allergy Clin Immunol. 2016;137(5):1347‐1358
- Leonard A, Wang J, Yu L, et al. Atopic Dermatitis Endotypes Based on
Allergen Sensitization, Reactivity to Staphylococcus aureus Antigens,
and Underlying Systemic Inflammation. J Allergy Clin Immunol Pract.
2020;8(1):236‐247.
- Jiao Q, Qian Q, Liu C, et al. T helper 22 cells from Han Chinese
patients with atopic dermatitis exhibit high expression of inducible
T-cell costimulator. Br J Dermatol. 2020;182(3):648‐657
- Ogg G. Natural killer cells get under your skin. Sci Transl
Med.2020;12(532):eaba9181
- Celebi Sözener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA.
Environmental factors in epithelial barrier dysfunction. J Allergy
Clin Immunol. 2020;145(6):1517‐1528
- Pavel AB, Zhou L, Diaz A, et al. The proteomic skin profile of
moderate-to-severe atopic dermatitis patients shows an inflammatory
signature. J Am Acad Dermatol. 2020;82(3):690‐699
- Guttman-Yassky E, Diaz A, Pavel AB, et al. Use of Tape Strips to
Detect Immune and Barrier Abnormalities in the Skin of Children With
Early-Onset Atopic Dermatitis JAMA Dermatol. 2019;155(12):1358‐1370
- Eyerich K, Brown SJ, Perez White BE, et al. Human and computational
models of atopic dermatitis: A review and perspectives by an expert
panel of the International Eczema Council. J Allergy Clin Immunol.
2019;143(1):36‐45
- Lemonnier N, Melén E, Jiang Y, et al. A novel whole blood gene
expression signature for asthma, dermatitis, and rhinitis
multimorbidity in children and adolescents [published online ahead
of print, 2020 Apr 11]. Allergy. 2020;10.1111/all.14314
- Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin
and lungs [published online ahead of print, 2020 Apr 22]. Allergy.
2020;10.1111/all.14318
- Agache I, Akdis CA. Endotypes of allergic diseases and asthma: An
important step in building blocks for the future of precision
medicine. Allergol Int. 2016;65(3):243‐252
- Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments for
asthma and skin allergies. Allergy. 2020;75(3):546‐560
- Ong PY. Moving toward a more precise treatment of atopic dermatitis.
Ann Allergy Asthma Immunol. 2018;120(1):3‐4.
- Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised trials.
BMJ. 2011;343:d5928
- Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the
quality of evidence–publication bias. J Clin Epidemiol.
2011;64(12):1277
- Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and
research outcome. Cochrane Database Syst Rev. 2017;2:MR000033.
- Bero LA. Why the Cochrane risk of bias tool should include funding
source as a standard item. Cochrane Database Syst Rev.
2013;(12):ED000075..
- Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of
methodological quality of economic evaluations: Consensus on Health
Economic Criteria. Int J Technol Assess Health Care. 2005;21(2):240-5.
- Hutter F, Antonanzas F. Economic evaluations in the EURONHEED: a
comparative analysis. Pharmacoeconomics. 2009;27(7):561-70.
- Nixon J, Rice S, Drummond M, et al. Guidelines for completing the
EURONHEED transferability information checklists. Eur J Health Econ.
2009;10(2):157-65
- Rucker G, Cates CJ, Schwarzer G. Methods for including information
from multi-arm trials in pairwise meta-analysis. Res Synth Methods.
2017;8(4):392-403.
- Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on
I2 in assessing heterogeneity may mislead. BMC medical research
methodology. 2008;8(1):79
- Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an
emerging consensus on rating quality of evidence and strength of
recommendations. BMJ. 2008;336(7650):924-6.
- Guyatt GH, Oxman AD, Sultan S, et al; GRADE Working Group. GRADE
guidelines. Rating up the quality of evidence. J Clin Epidemiol.
2011;64(12):1311-6
- Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and
guidelines for the SCORAD index: consensus report of the European Task
Force on Atopic Dermatitis. Dermatology. 1997;195(1):10‐19.
- Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and
POEM for atopic eczema: responsiveness and minimal clinically
important difference. Allergy 2012; 67: 99-106
- Hanifin JM, Thurston M, Omoto M, ey al. The eczema area and severity
index (EASI): assessment of reliability in atopic dermatitis. EASI
Evaluator Group. Exp Dermatol 2001; 10: 11-8.
- Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure:
development and initial validation of a new tool for measuring atopic
eczema severity from the patients’ perspective. Arch Dermatol 2004;
140: 1513-19.
- Basra MK, Salek MS, Camilleri L, et al. Determining the minimal
clinically important difference and responsiveness of the Dermatology
Life Quality Index (DLQI): further data. Dermatology.
2015;230(1):27-33.
- Simpson EL, de Bruin-Weller M, Eckert L, et al. Responder Threshold
for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology
Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis.
Dermatol Ther (Heidelb). 2019;9(4):799‐805
- Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity:
prospective study on validity and reliability of the visual analogue
scale, numerical rating scale and verbal rating scale in 471 patients
with chronic pruritus. Acta Derm Venereol 2012; 92: 502-7.
- Reich A, Halupczok J, Ramus M, et al. New data on the validation of
VAS and NRS in pruritus assessment: minimal clinically important
difference and itch frequency measurement. Acta Derm Venereol 2011;
91: 636.
- Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the
Hospital Anxiety and Depression Scale. An updated literature review. J
Psychosom Res. 2002;52(2):69‐77
- Santesso 2020: Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper
B, GRADE Working Group, et.al. GRADE guidelines 26: informative
statements to communicate the findings of systematic reviews of
interventions. J Clin Epidemiol. 2020; 119:126-135.
- Thaçi D, Simpson EL, Beck LA, et.al. Efficacy and safety of dupilumab
in adults with moderate-to-severe atopic dermatitis inadequately
controlled by topical treatments: a randomised, placebo-controlled,
dose-ranging phase 2b trial. Lancet. 2016; 387(10013):40-52
- Simpson EL, Bieber T, Guttman-Yassky E, et.al. SOLO 1 and SOLO 2
Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in
Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-2348
- Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term
management of moderate-to-severe atopic dermatitis with dupilumab and
concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year,
randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet.
2017;389(10086):2287-2303.
- de Bruin-Weller M, Thaçi D, Smith CH, et. al. Dupilumab with
concomitant topical corticosteroid treatment in adults with atopic
dermatitis with an inadequate response or intolerance to ciclosporin A
or when this treatment is medically inadvisable: a placebo-controlled,
randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol.
2018; 178(5):1083-1101
- Simpson EL, Paller AS, Siegfried EC, et al.. Efficacy and Safety of
Dupilumab in Adolescents with Uncontrolled Moderate to Severe Atopic
Dermatitis: a Phase 3 Randomized Clinical Trial. AMA Dermatol.
2019;156(1):44-56.
- Worm M, Simpson EL, Thaci D, Bissonnette R, Lacour JP, Beissert S, et
al. Efficacy and Safety of Multiple Dupilumab Dose Regimens After
Initial Successful Treatment in Patients With Atopic Dermatitis: A
Randomized Clinical Trial. JAMA Dermatol. 2019; 156(2):131-143.
- ICER. Institute for Clinical and Economic Review. Dupilumab and
Crisaborole for Atopic Dermatitis: Effectiveness and Value. Evidence
Report; 2017. Available from:
https://icer-review.org/material/atopic-dermatitis-evidence-report/.
Accessed December 7, 2019.
- Kuznik A, Bégo-Le-Bagousse G, Eckert L, et al. Economic Evaluation of
Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in
Adults. Dermatol Ther (Heidelb). 2017; 7(4): 493-505.
- Zimmermann M, Rind D, Chapman R, et al. Economic Evaluation of
Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility
Analysis. J Drugs Dermatol. 2018; 17(7): 750-756
- CADTH 2020] CADTH. Canadian Agency for Drugs and Technologies in
Health. Common drug review. Pharmacoeconomic review report. Dupilumab
(DUPIXENT. Sanofi-Aventis Canada Inc.). Moderate-to-severe atopic
dermatitis. 2018. Available
from:https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0533_Dupixent_PE_Report.pdf.
Accessed May 20, 2020
- NICE. Dupilumab for treating moderate to severe atopic dermatitis.
Technology appraisal guidance. 2018. Available from:
www.nice.org.uk/guidance/ta534. Accessed May 20, 2020.
- Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the
curious resilience of the $50,000-per-QALY threshold. N Engl J Med.
2014;371(9):796-7.
- Edwards HA, McMeniman EK. The cost of dupilumab treatment for severe
atopic dermatitis is largely offset by broader health-care savings and
improvement in quality of life. Australas J Dermatol.
2020;61(2):e273-e275
- Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in
moderate-to-severe atopic dermatitis: A systematic review and
meta-analysis. J Dermatol Sci. 2018;90(2):190-198.
- Snast I, Reiter O, Hodak E, et al. Are Biologics Efficacious in Atopic
Dermatitis? A Systematic Review and Meta-Analysis. Am J Clin Dermatol.
2018;19(2):145-165.
- Drucker AM, Ellis AG, Bohdanowicz M, et.al. Systemic Immunomodulatory
Treatments for Patients With Atopic Dermatitis: A Systematic Review
and Network Meta-analysis. JAMA Dermatol. 2020;156(6):1-10.
- Wollenberg A, Beck LA, Blauvelt A, et al. Assessing the need for
routine safety testing for patients being treated with dupilumab for
moderate-to-severe atopic dermatitis. Br J Dermatol.
2020;182(6):e186-e209.
- Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety
and efficacy in patients with moderate to severe atopic dermatitis
enrolled in a phase 3 open-label extension study. J Am Acad Dermatol.
2020;82(2):377-388
- Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with
uncontrolled moderate-to-severe atopic dermatitis: results from a
phase IIa open-label trial and subsequent phase III open-label
extension. Br J Dermatol . 2020;182(1):85-96
- Bosma AL, de Wijs LEM, Hof MH, et al. Long-term effectiveness and
safety of treatment with dupilumab in patients with atopic dermatitis:
results of the TREAT NL (TREatment of ATopic eczema, the Netherlands)
registry [published online ahead of print, 2020 May 30]. J Am Acad
Dermatol. 2020;S0190-9622(20)31004-5.